MMM.E. Malushkova

M.E. Malushkova

*This is an algorithmically generated author record based on publicly available information.

M.E. Malushkova has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Adrenal cysts clinically mimicking cancer (three clinical observations and literature review)

    by A.M. Lavrova, N.N. Volchenko, M.E. Malushkova, M.P. Mazurova

    Adrenal cysts are an extremely rare heterogeneous group of adrenal gland lesions of various etiologies and pathogenesis, as well as clinical manifestations. They can range from non-tumorous cystic lesions to benign or malignant cystic neoplasms. Typically, non-tumorous adrenal cysts are asymptomatic and are detected incidentally during radiological examinations for other medical conditions. With the advancement and increased availability of radiological diagnostic methods, the incidence of non-tumorous adrenal cysts is increasing. In this report, we describe 3 clinical cases of non-tumorous adrenal cysts.

  • A differentiated approach to thymectomy in generalized form of myasthenia gravis

    by D.E. Martynova, O.V. Pikin, N.I. Shcherbakova, A.B. Ryabov, V.V. Barmin, V.A. Bagrov, M.E. Malushkova, Z.M. Salimov

    Objective. To identify clinical and morphological factors associated with favorable neurological outcomes after extended thymectomy in patients with generalized myasthenia gravis. Material and methods. A single-center retrospective study with prospective component included 103 patients with generalized myasthenia gravis who underwent extended thymectomy in 2009–2021. The primary endpoint was improvement in the Myasthenia Gravis Foundation of America (MGFA) Postintervention Status classification: sustained remission, pharmacological remission, or minimal manifestations. Potential predictors included thymus morphology, thymoma, period between manifestation and surgery, immunopathogenetic variant of myasthenia, preoperative QMG score, age, gender and characteristics of disease onset. Results. Improvement was achieved in 73 out of 103 patients (70.9%) after 3 years. Favorable outcome was more common in thymic hyperplasia compared to thymic involution (75.5% vs 66.0%), in patients without thymoma than in those with thymoma (73.3% vs 53.8%), as well as in case of surgery within 2 years after manifestation (76.7% vs 62.8%). Preoperative QMG cutoff of 26.5 identified patients with higher risk of no improvement (odds ratio 4.0; 95% CI 1.64–10.08; p = 0.02). Thymectomy efficacy was 74.5% in AChR-positive, 54.0% in MuSK-positive, and 33.0% in seronegative myasthenia gravis. Postoperative complications occurred in 4 patients (3.8%), conversion was required in 3 patients (2.9%), and no deaths or postoperative myasthenic crises were recorded. Conclusion. Preoperative stratification before thymectomy in generalized myasthenia gravis should integrate QMG score, disease time, thymoma status, and thymic morphology. QMG combined with clinical and morphological variables may be useful for predicting the expected benefit of surgery and for patient counseling.

  • Lung adenocarcinoma combined with neuroendocrine «tumorlets»

    by N.N. Volchenko, A.M. Lavrova, M.E. Malushkova, N.S. Goeva

    Neuroendocrine tumors are a group of malignant neoplasms that differs from each other in morphology, immunophenotype, molecular genetic profiles, biological and clinical behavior. Neuroendocrine tumors more frequently occur in the gastrointestinal tract and the respiratory system, predominantly in lungs. According to the classification of the World Health Organization, there are neuroendocrine tumors with low and intermediate malignant potential (typical and atypical carcinoid), with high malignant potential (small cell and large cell carcinoma) in lungs. Neuroendocrine cell hyperplasia and neuroendocrine «tumorlets» are preinvasive neuroendocrine lung lesions. We describe 5 cases of invasive lung adenocarcinomas combined with neuroendocrine «tumorlets», which were identified during pathological research of surgical material.


  • Possibilities of drug treatment for pseudomyxoma peritonei of appendiceal origin

    by V.S. Trifanov, N.A. Grishin, N.N. Volchenko, A.L. Kornietskaya, M.E. Malushkova, S.I. Poluektov, M.V. Kosogolov

    The article is devoted to a rather rare pathology — mucinous tumor of the appendix with the formation of pseudomyxoma peritonei. There are currently no generally accepted clinical recommendations based on the results of randomized clinical trials regarding the treatment of this pathology. The role of drug therapy for pseudomyxoma peritonei is an understudied topic, but current evidence suggests that there is a lack of highly effective systemic therapy regimens. This paper demonstrates a clinical observation of the successful treatment of a patient with pseudomyxoma peritonei of appendiceal origin based on a personalized approach taking into account the molecular genetic features of the tumor.

  • Small cell carcinoma of the parotid gland

    by M.V. Bogatyreva, L.I. Moskvicheva, M.E. Malushkova, O.B. Shitikova, E.V. Gameeva

    Tumors of the salivary glands are rare; in the vast majority of cases, they are localized in the parotid salivary gland and can be malignant or benign. Primary small cell cancer of the parotid salivary gland develops more often in men aged 50—80 years and is clinically manifested as a painless, fast-growing node. The diagnosis of these tumors is based on immunohistochemical confirmation of simultaneous epithelial and neuroendocrine differentiation. Due to the rarity of primary neuroendocrine small cell cancer of the parotid salivary gland, there is no specific generally accepted treatment regimen. Currently, surgical, radiation, and medicinal methods of antitumor treatment are used in such situations. Chemotherapy regimens usually include platinum preparations in combination with other medicinal agents. This article presents a clinical case of palliative chemotherapy in a patient with bilateral synchronous small cell carcinoma of this localization.

  • Hepatocellular carcinoma associated with nonalcoholic fatty liver disease

    by V.S. Trifanov, V.V. Kopylov, N.A. Grishin, N.N. Volchenko, M.E. Malushkova, A.A. Troitsky, R.I. Moshurov, S.I. Poluektov, M.V. Kosogolov

    The clinical observation is devoted to the successful surgical treatment of a patient with primary liver cancer that developed against the background of non-alcoholic fatty liver disease. This pathology as a predictor of hepatocellular carcinoma has recently come out on top in frequency, displacing hepatitis and cirrhosis of viral etiology. The literature review provides data on the incidence of steatosis and steatohepatitis in developed countries of the world, as well as mechanisms of hepatocarcinogenesis against the background of these conditions, morphological characteristics of these subtypes of liver carcinoma, and diagnostic difficulties.